Literature DB >> 26968558

Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease.

Mei Lin1, Ping Gao2, Tianya Zhao1, Lei He1, Mengshi Li1, Yaoyao Li1, Hua Shui1, Xiaoyan Wu1.   

Abstract

To investigate the effects of calcitriol on angiotensin-converting enzyme (ACE) and ACE2 in diabetic nephropathy. Streptozotocin (STZ) induced diabetic rats were treated with calcitriol for 16 weeks. ACE/ACE2 and mitogen activated protein kinase (MAPK) enzymes were measured in the kidneys of diabetic rats and rat renal tubular epithelial cells exposed to high glucose. Calcitriol reduced proteinuria in diabetic rats without affecting calcium-phosphorus metabolism. ACE and ACE2 levels were significantly elevated in diabetic rats compared to those in control rats. The increase in ACE levels was greater than that of ACE2, leading to an elevated ACE/ACE2 ratio. Calcitriol reduced ACE levels and ACE/ACE2 ratio and increased ACE2 levels in diabetic rats. Similarly, high glucose up-regulated ACE expression in NRK-52E cells, which was blocked by the p38 MAPK inhibitor SB203580, but not the extracellular signal-regulated kinase (ERK) inhibitor FR180204 or the c-Jun N-terminal kinase (JNK) inhibitor SP600125. High glucose down-regulated ACE2 expression, which was blocked by FR180204, but not SB203580 or SP600125. Incubation of cells with calcitriol significantly inhibited p38 MAPK and ERK phosphorylation, but not JNK phosphorylation, and effectively attenuated ACE up-regulation and ACE2 down-regulation in high glucose conditions. The renoprotective effects of calcitriol in diabetic nephropathy were related to the regulation of tubular levels of ACE and ACE2, possibly by p38 MAPK or ERK, but not JNK pathways.

Entities:  

Keywords:  Angiotensin converting enzyme; Angiotensin converting enzyme 2; Calcitriol; Diabetic kidney disease

Mesh:

Substances:

Year:  2016        PMID: 26968558     DOI: 10.1007/s11033-016-3971-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  42 in total

1.  Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.

Authors:  Maria-Dolores Sanchez-Niño; Milica Bozic; Elizabeth Córdoba-Lanús; Petya Valcheva; Olga Gracia; Merce Ibarz; Elvira Fernandez; Juan F Navarro-Gonzalez; Alberto Ortiz; Jose Manuel Valdivielso
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-14

2.  Functional, molecular, and biochemical characterization of streptozotocin-induced diabetes.

Authors:  Donald T Ward; S Kam Yau; Andrew P Mee; E Barbara Mawer; Christopher A Miller; Hugh O Garland; Daniela Riccardi
Journal:  J Am Soc Nephrol       Date:  2001-04       Impact factor: 10.121

Review 3.  ACE and ACE2 in kidney disease.

Authors:  Sonoo Mizuiri; Yasushi Ohashi
Journal:  World J Nephrol       Date:  2015-02-06

4.  Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

Authors:  Minghao Ye; Jan Wysocki; Josette William; Maria José Soler; Ivan Cokic; Daniel Batlle
Journal:  J Am Soc Nephrol       Date:  2006-10-04       Impact factor: 10.121

5.  Parathyroid hormone-potentiated connective tissue growth factor expression in human renal proximal tubular cells through activating the MAPK and NF-kappaB signalling pathways.

Authors:  Yunshan Guo; Weijie Yuan; Ling Wang; Minghua Shang; Yan Peng
Journal:  Nephrol Dial Transplant       Date:  2010-09-01       Impact factor: 5.992

Review 6.  ACE2 alterations in kidney disease.

Authors:  María José Soler; Jan Wysocki; Daniel Batlle
Journal:  Nephrol Dial Transplant       Date:  2013-08-16       Impact factor: 5.992

7.  Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor.

Authors:  Matthew J Huentelman; Jasenka Zubcevic; Jose A Hernández Prada; Xiaodong Xiao; Dimiter S Dimitrov; Mohan K Raizada; David A Ostrov
Journal:  Hypertension       Date:  2004-10-18       Impact factor: 10.190

8.  Tuberin inhibits production of the matrix protein fibronectin in diabetes.

Authors:  Samy L Habib; Mukesh Yadav; Shaza Tizani; Basant Bhandari; Anthony J Valente
Journal:  J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 10.121

9.  1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter.

Authors:  Weihua Yuan; Wei Pan; Juan Kong; Wei Zheng; Frances L Szeto; Kari E Wong; Ronald Cohen; Anna Klopot; Zhongyi Zhang; Yan Chun Li
Journal:  J Biol Chem       Date:  2007-08-09       Impact factor: 5.157

Review 10.  Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets.

Authors:  Fan Jiang; Jianmin Yang; Yongtao Zhang; Mei Dong; Shuangxi Wang; Qunye Zhang; Fang Fang Liu; Kai Zhang; Cheng Zhang
Journal:  Nat Rev Cardiol       Date:  2014-04-29       Impact factor: 49.421

View more
  13 in total

1.  Editorial over the Many Faces of Vitamin D in Chronic Kidney Disease: from Mineral to Immune-Inflammatory Modulator.

Authors:  Patrick M Honore; Herbert D Spapen
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

Review 2.  Intrarenal Angiotensin-Converting Enzyme: the Old and the New.

Authors:  Silas Culver; Caixia Li; Helmy M Siragy
Journal:  Curr Hypertens Rep       Date:  2017-09-19       Impact factor: 5.369

Review 3.  Vitamin D and COVID-19: Role of ACE2, age, gender, and ethnicity.

Authors:  Bruk Getachew; Yousef Tizabi
Journal:  J Med Virol       Date:  2021-05-19       Impact factor: 20.693

4.  Vitamin D can prevent COVID-19 infection-induced multiple organ damage.

Authors:  Hatice Aygun
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-05-25       Impact factor: 3.000

Review 5.  Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.

Authors:  Soudeh Ghafouri-Fard; Rezvan Noroozi; Mir Davood Omrani; Wojciech Branicki; Ewelina Pośpiech; Arezou Sayad; Krzysztof Pyrc; Paweł P Łabaj; Reza Vafaee; Mohammad Taheri; Marek Sanak
Journal:  Vascul Pharmacol       Date:  2020-05-11       Impact factor: 5.773

Review 6.  Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction - A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic.

Authors:  Aida Santaolalla; Kerri Beckmann; Joyce Kibaru; Debra Josephs; Mieke Van Hemelrijck; Sheeba Irshad
Journal:  Front Physiol       Date:  2020-11-26       Impact factor: 4.566

Review 7.  Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.

Authors:  Ming-Yieh Peng; Wen-Chih Liu; Jing-Quan Zheng; Chien-Lin Lu; Yi-Chou Hou; Cai-Mei Zheng; Jenn-Yeu Song; Kuo-Cheng Lu; You-Chen Chao
Journal:  Int J Mol Sci       Date:  2021-05-16       Impact factor: 5.923

Review 8.  A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.

Authors:  Aida Malek Mahdavi
Journal:  Rev Med Virol       Date:  2020-06-25       Impact factor: 11.043

9.  Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: a systematic review.

Authors:  Hajira Dambha-Miller; Ali Albasri; Sam Hodgson; Christopher R Wilcox; Shareen Khan; Nazrul Islam; Paul Little; Simon J Griffin
Journal:  BMJ Open       Date:  2020-09-14       Impact factor: 2.692

Review 10.  Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.

Authors:  Sang Heon Suh; Seong Kwon Ma; Soo Wan Kim; Eun Hui Bae
Journal:  Korean J Intern Med       Date:  2020-10-16       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.